Aftamed Oral Spray is NOT Suitable for an 8-Month-Old Infant
Do not use Aftamed (chlorhexidine gluconate) oral spray in an 8-month-old infant—the FDA-approved labeling explicitly contraindicates its use in children under 2 years of age. 1
Clear Age Restriction from FDA Labeling
The FDA drug label for Aftamed provides unambiguous direction: the product is approved for "adults and children 2 years of age and older" and specifically states "Children under 2 years of age: Do not use, consult your doctor." 1 This is a regulatory contraindication, not merely a precautionary statement.
Safety Concerns with Chlorhexidine in Young Infants
The restriction exists for important safety reasons documented in pediatric literature:
Systemic Absorption Risk: Chlorhexidine can be absorbed through mucous membranes and immature skin barriers. Research demonstrates that infants under 2 months show detectable blood levels of chlorhexidine after topical application, with all studied infants showing evidence of absorption and some reaching levels ≥100 ng/mL 2. The clinical significance of these blood levels remains unknown.
Skin and Mucosal Injury: Chlorhexidine has caused chemical burns, contact dermatitis, and blistering in premature and young infants, particularly those under 36 weeks gestational age 3. While most documented cases involve preterm infants, the immature epithelial barriers of young infants (including 8-month-olds with developing oral mucosa) present similar concerns.
Contact Sensitization: Case series confirm that chlorhexidine causes allergic contact dermatitis in young children, with documented cases as young as 8 months of age 4. Benzalkonium chloride (often present in formulations) is similarly implicated.
Regulatory and Professional Guidance Context
The Society for Healthcare Epidemiology of America explicitly states that "chlorhexidine products are not approved by the US Food and Drug Administration for children younger than 2 months of age" 5, and this caution extends to oral mucosal applications in all infants under 2 years per the Aftamed labeling.
Clinical Bottom Line
For oral lesions or mouth discomfort in an 8-month-old, consult the child's pediatrician for age-appropriate alternatives. The FDA contraindication is absolute and based on insufficient safety data in this age group. The potential risks of mucosal absorption, local tissue injury, and allergic sensitization outweigh any theoretical benefits, particularly when safer alternatives exist for pediatric oral care.